MUVON joins EAU’s Urge to Act campaign during Urology Week
Zurich, Switzerland, September 25, 2023 – MUVON Therapeutics, a leading Swiss biotech startup, is advancing a minimally-invasive personalized tissue-engineered regenerative therapy for female urinary incontinence.
During Urology Week (24-30 September), MUVON Therapeutics joins the European Association of Urology (EAU) and supports their Urge to Act campaign focused on making policymakers aware that there are novel approaches under investigation to improve continence health across Europe.
Dr John Coelho, Medical Affairs Leader of MUVON, stated:
“We are advancing a first-in-class regenerative tissue engineered therapy indicated for incontinence and join the European Association of Urology over this week celebrating our own scientist-leaders Deana Mohr and Jenny Prange who won the Female Innovator of the Year Award at the 6th Female Innovation Forum.”
Urinary incontinence is medical condition which is impacting the quality of life of 45% Europeans, and consequently the larger European health system, the economy and the environment due to waste disposal.
In 2023, the population healthcare cost of continence care will go up to 40 billion Euros. Since continence problems intensify as people age, and as the European population is aging at a rapid pace, a total accumulated economic burden of almost 320 billion Euros is predicted by 2030.
If no action is taken to support continence health, incontinence will become a major health problem in Europe. So, urgent policy action is needed.
The Urge to Act campaign calls for substantial transformation from policymakers to recognize and ease the 40-billion-euro burden on continence in Europe through improved diagnosis, care and interventions.
About Stress Urinary Incontinence
Stress Urinary Incontinence is defined as the involuntary loss of urine while coughing, sneezing, laughing, or exercising, due to weakened pelvic and / or sphincter muscles.
About MUVON’s technology
MUVON’s revolutionary cutting-edge technology uses patients’ own cells to restore natural muscle function. The principle is simple. From a small muscle biopsy, muscle precursor cells are isolated and multiplied under strictly controlled and optimized conditions. Following a rigorous quality control, the final product is injected directly into the patient’s damaged sphincter muscle. The cells begin to form new muscle fibers which integrate with the existing muscle tissue, restoring function. The results from the Phase I clinical trial demonstrated the safety, feasibility, and potential efficacy of the MUVON’s therapy. No serious or unexpected adverse events were observed.
For more information, please contact:
Dr Deana Mohr, CEO
About MUVON Therapeutics AG
MUVON Therapeutics, founded in 2020 as a clinical-stage company, is a spin-off from the University of Zurich, currently being accelerated by the Wyss Zurich Translational Center. MUVON Therapeutics is dedicated to the discovery and development of personalized regenerative treatments with the goal of establishing them as an affordable standard of care. Our mission is to help the millions of patients suffering from serious debilitating diseases regain control of their lives by offering the minimally invasive treatment for regeneration of skeletal muscle tissue. For more information about MUVON Therapeutics, please visit: www.muvon-therapeutics.com